Zobrazeno 1 - 10
of 276
pro vyhledávání: ''
Autor:
Timon E. Adolph, Konrad Aden, Simon Reider, Maria Effenberger, Silvio Waschina, Barbara Enrich, Philip Rosenstiel, Alexander R. Moschen, Robert Koch, Herbert Tilg, Christina Bronowski
Publikováno v:
Journal of Crohn's and Colitis. 15:88-98
Background and Aims The microbial ecosystem seems to be an important player for therapeutic intervenption in inflammatory bowel disease [IBD]. We assessed longitudinal microbiome changes in IBD patients undergoing therapy with either azathioprine [AZ
Publikováno v:
Lund, K, Larsen, M D, Knudsen, T, Kjeldsen, J, Nielsen, R G & Nørgård, B M 2021, ' Infliximab, Immunomodulators and Treatment Failures in Paediatric and Adolescent Patients with Crohn's Disease : a nationwide cohort study ', Journal of Crohn's and Colitis, vol. 15, no. 4, pp. 575–582 . https://doi.org/10.1093/ecco-jcc/jjaa188
Background and Aims In paediatric patients with Crohn’s disease, the role of combination therapy, infliximab plus immunomodulators [thiopurine or methotrexate], is debated and data are sparse. We examined whether infliximab plus immunomodulators, c
Autor:
Y. Gonzalez Lama, I Omella Usieto, V Matallana Royo, P Bella del Castillo, I. El Hajra Martinez, M I Vera Mendoza, E. Santos Perez, R De Lucas Téllez de Meneses, B Menchen Viso, B. Ruiz Antoran, M I Calvo Moya, M González Rodriguez, I Gonzalez Partida
Publikováno v:
Journal of Crohn's and Colitis. 15:S507-S509
Background Adalimumab (ADA) intensification is recommended for inadequate or loss of response in inflammatory bowel disease (IBD) patients. A new presentation of ADA 80mg administered every other week (eow) has been approved as an alternative to ADA
Autor:
C Suárez, F Mesonero Gismero, M C Rodríguez-Grau, M Vicuña, Federico Bertoletti, B Caballol, Y Zabana, María García, C Rubín de Célix, Miguel Montoro, José Manuel Benítez, José Miranda-Bautista, R Nájera, G Suris, N García-Morales, E Brunet, A Elosua, I González, M Piqueras, A Sobrino, Leyanira Torrealba, Agnès Fernández-Clotet, A Castaño, A Gutiérrez, A López-García, M. Barreiro-de Acosta, E Leo, B. Casis, R Ferreiro-Iglesias, A Núñez, L Ramos, A Mínguez, R M Sáiz, L J Lamuela, A.D Hernández, I Fajardo, Antonio López-Sanromán, Ignacio A. Jiménez, M Calafat, C Tejido
Publikováno v:
Journal of Crohn's and Colitis. 15:S388-S390
Background Pouchitis and other inflammatory disorders of the pouch (IDP), such as Crohn′s-like disease of the pouch (CDP), are frequent in patients operated for a previous diagnosis of ulcerative colitis. Many different therapies have been used, bu
Autor:
Edouard Louis, Nicolas Pierre, Mathieu Allez, Marie-Alice Meuwis, Y. Bouhnik, D. Laharie, Arnaud Bourreille, J.-F. Colombel, Vân Anh Huynh-Thu
Publikováno v:
Journal of Crohn's and Colitis. 15:S011-S013
Background In Crohn’s disease (CD), biologics can induce mucosal healing and stable remission. After reaching this target, treatment de-escalation could be considered but the risk of relapse needs to be estimated. Current biomarkers used to predict
Publikováno v:
Journal of Crohn's and Colitis. 15:S063-S065
Background Despite widespread use of therapeutic drug monitoring to guide anti-TNF biologic prescribing in IBD, its role for other biologic classes remains unclear. The present study aimed to assess the relationship between early vedolizumab trough c
Autor:
Erwin Dreesen, Marc Ferrante, Severine Vermeire, G. D'Haens, A Buisson, Bas Oldenburg, Ron A. A. Mathôt, D. Laharie, Wannee Kantasiripitak
Publikováno v:
Journal of Crohn's and Colitis. 15:S481-S483
Background The endoscopic healing index (EHI) is a novel multi-protein serum biomarker test developed and validated to assess endoscopic disease activity in patients with Crohn’s disease (CD). Evidence for the use of EHI to guide decision-making du
Autor:
Rahul S. Dalal, Edward L. Barnes, Jessica R. Allegretti, Jenna Marcus, Scott Esckilsen, Jordan C. Pruce
Publikováno v:
Journal of Crohn's and Colitis. 15:S296-S298
Background Patients with ulcerative colitis (UC) on ustekinumab (UST) therapy may have suboptimal response to standard every 8 week (q8w) dosing. Empiric dose escalation to q4w or q6w is common, but the efficacy of these strategies are unknown in UC.
Autor:
S Viera-Silva, Kathleen Machiels, Bram Verstockt, Jeroen Raes, Clara Caenepeel, Marc Ferrante, N A Davani, João Sabino, Severine Vermeire
Publikováno v:
Journal of Crohn's and Colitis. 14:S016-S018
Background The expansion of therapeutic options in IBD brought forward a need to personalise treatment. Gut inflammation in inflammatory bowel disease (IBD) patients has been associated with reduced microbial richness and abundance of SCFA producers.
Autor:
Nidhi Srivastava, M Löwenberg, R West, Colitis (Icc), D. de Jong, Bas Oldenburg, Biemans drs, Frank Hoentjen, A van der Meulen de Jong, G Dijkstra, Alexander Bodelier, N. K. H. de Boer, J. van der Woude, Jochen Jansen, Marie J. Pierik, Jeoffrey J L Haans, A C de Vries
Publikováno v:
Journal of Crohn's and Colitis. 14:S114-S116
Background Both vedolizumab and ustekinumab can be considered for the treatment of Crohn’s disease (CD) when anti-TNF treatment fails. However, head-to-head trials are currently not available or planned in the near future. The aim of this study was